Positive phase III data gives Merck potential boost for blockbuster Keytruda in injection form
Merck released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA ...
TMCnet3d
ERS Genomics and Jumpcode Genomics sign CRISPR/Cas9 license agreement
ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Jumpcode Genomics ('Jumpcode'), a life science tools company ...
CAR T-Cell Therapy Market Size To Reach 27.5 Billion by 2033 Owing to Rising Awareness and Favourable Reimbursement Policies Says Astute Analytica
The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, reflecting a robust CAGR of 26.2%.
Merck & Co. Inc. stock outperforms competitors on strong trading day
Merck & Co. Inc. closed 33.72% short of its 52-week high of $134.63, which the company achieved on June 25th.
Merck & Co.: Looming Patent Expiries For Key Drugs Weaken Longer-Term Outlook
Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Merck & Co., Inc. (MRK) Shareholders
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn ...
Reuters3d
Merck plans to launch US subcutaneous version of Keytruda on October 1
NEW YORK, March 27 (Reuters) - Merck & Co (MRK.N), opens new tab said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the ...
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE:MRK) between February 3, 2022 and ...
Is Merck & Co. (MRK) The Best Healthcare Dividend Stock to Invest in?
We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look ...
FierceBiotech5d
Merck & Co. pens $200M upfront deal for Hengrui's midstage heart disease med
Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor. In return for the ex-China rights to the drug, dubbed HRS-5346 ...